A Study of Two Associations of Rituximab and Chemotherapy, With a PET-driven Strategy, in Lymphoma
Status:
Completed
Trial end date:
2013-10-01
Target enrollment:
Participant gender:
Summary
This Phase II study randomized R-ACVBP and R-CHOP as induction treatment in patients from 18
to 59 with DLBCL CD20+ lymphoma and 2 or 3 adverse prognostic factors of the age-adjusted
IPI. The consolidation treatment is allocated according to the response to induction
treatment assessed by PET after the 2nd and 4th induction cycles.